[Substantiation of increasing the quality of disease-modifying therapy for multiple sclerosis using in the Russian Federation].  The problems of using disease-modifying drugs in treatment of multiple sclerosis related to the difficulties of the control over the quality of bioanalogues imported into or manufactured in the Russian Federation are discussed.
